

Swiss edition
Data as at end-November 2024
ISIN: LU0200191152


# **UBS Strategy Xtra Fund Balanced USD**

## Performance Review

UBS (Lux) Strategy Xtra SICAV - Balanced (USD) P-acc



### Performance (basis USD, net of fees)1



Fund performance per year in % net of fees (right-hand scale)

Past performance is not a reliable indicator of future results.

## Performance in % (net of fees)1

in %	2020	2021	2022	2023	2024	Nov.	5 years Ø	p.a. 5
					YTD2	2024		years
Fund (USD)	7.58	7.38	-12.50	8.26	7.42	1.23	19.54	3.63

The performance shown does not take account of any commissions, entry or exit charges.

- 1 These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.
- Management.
  2 YTD: year-to-date (since beginning of the year)

The US elections took the spotlight, with Donald Trump being elected president for a second term in a "red sweep". In the aftermath of the polls, the focus switched to Trump's potential policy changes with regard to tariffs, immigration, tax cuts and administration picks. Central banks continued the rate-cutting cycle, with the Fed and the Bank of England in particular cutting rates by 25 basis points.

## Monthly performance

In November the fund performed positively with 1.2%. Trump's potential pro-growth policy implementations spurred on US and, by extension, world stocks to their best monthly performance of the year. Against the backdrop of the continued ratecutting cycle, returns on fixed income markets were positive.

## YTD performance

YTD as of the end of November, the fund has delivered a positive performance of 7.4%. Both equities and fixed income have contributed positively to performance. The main performance drivers in equities have been global stocks in the developed markets excluding Switzerland. In fixed income, USD corporate and USD high-grade bonds have contributed the most. Hedge funds and risk parity have also made notable contributions.

## **Performance contributors**

Both fixed income and equities contributed positively, with equities leading the way. Global equities in the developed markets excluding Switzerland were the biggest contributors from the equity space, while in fixed income, high-grade and corporate bonds made the largest contributions. Hedge funds and risk parity made flat contributions.

## **Performance detractors**

Emerging market equities were the biggest detractors during the month.

For more information

UBS Fund Infoline: 0800 899 899

Internet: www.ubs.com/funds Contact your client advisor

## Portfolio management representatives

Sebastian Richner Roland Kramer Daniel Hammar

## UBS Strategy Xtra Fund Balanced USD

### Current allocation by sub-asset class in %

	Current allocation
Liquidity	9.5
High grade bonds	11.0
USD inflation linked bonds	4.0
USD corporate bonds	8.0
EUR corporate bonds	0.0
USD high yield bonds	3.0
EUR high yield bonds	2.0
Emerging market sovereign bonds	3.0
Emerging market corporate bonds	2.0
Cash synth	-7.0
Other fixed income	0.0
Bonds	26
Switzerland	1.8
United States	25.2
Eurozone	6.5
United Kingdom	3.8
Emerging markets	5.2
Japan	4.6
Canada	0.0
Australia	-0.1
Sweden	-0.1
Hong Kong	-0.1
Singapore	0.2
Global	1.5
Equities	48.5
Hedge funds	11.0
Risk Parity	4.0
Commodity	1.0
Alternative Investments	16
Total	100

For illustrative purposes only. Current allocation may be changed at any time without prior notice. The allocation is based on the model portfolio of the strategy. Due to implementation exceptions, actual exposures may deviate. Foreign currency risks are largely hedged against the reference currency

## 10 largest equity positions (%)

	Fund
Microsoft Corp	1.40
Amazon.com Inc	1.33
Taiwan Semiconductor Manufacturing Co Ltd	0.73
Broadcom Inc	0.68
NVIDIA Corp	0.62
ServiceNow Inc	0.59
Take-Two Interactive Software Inc	0.48
Apollo Global Management Inc	0.48
UnitedHealth Group Inc	0.46
Koninklijke Philips NV	0.46

## Current investment strategy

Over the course of the month, we implemented a position in 5-year US Treasuries versus cash to position for lower interest rates. We maintained our overweight in US equities at the expense of cash, as well as our overweight in IT equities versus global equities. Currency-wise, we closed the FX basket (long in the AUD, EUR, CHF and GBP versus the USD), and we are now overweight in the USD versus the CNY.

#### Risks

The fund invests in equities, bonds of varying credit quality, money market securities on a global basis, as well as in alternative forms of investment such as hedge funds. It may therefore be subject to fluctuations in value. The fund may use derivatives which can reduce investment risk or give rise to additional risks (inter alia the counterparty risk). The fund can invest in less liquid assets that may be difficult to sell in the case of distressed markets. It therefore cannot be ruled out that the daily issue and redemption of fund units may be suspended temporarily. The value of a unit may fall below the purchase price. This requires an elevated risk tolerance and capacity. Every fund reveals specific risks, a description of these risks can be found in the prospectus. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

## 5 largest bond issuers (%)

	Fund
STAR Compass PLC	7.72
United States Treasury Note/Bond	5.36
United States Treasury Inflation Indexed Bonds	2.58
United States Treasury Inflation Indexed Bonds - When Issued	1.32
International Bank for Reconstruction & Development	0.55

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary © UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.